AML Gene-Edited Cell Lines for Drug Discovery and Research

Acute Myeloid Leukemia (AML) is a heterogeneous hematologic malignancy with an estimated 20,380 new cases and 11,310 deaths in the United States in 2023 (NCI SEER). The global age-standardized incidence rate is approximately 4.3 per 100,000 person-years (WHO GLOBOCAN 2020). Key risk factors include advanced age, prior chemotherapy, ionizing radiation, and inherited genetic syndromes. The 5-year relative survival rate for AML is 31.7% overall, but it drops to less than 10% for patients over 65 years (NCI SEER 2013-2019). Despite advances in targeted therapies, relapse remains a major clinical challenge, driving the need for better preclinical models.

AML is an ideal disease for mechanistic studies due to its well-characterized genetic landscape, the availability of large public datasets (TCGA, COSMIC, DepMap), and the presence of recurrent, druggable mutations. Open questions include the role of clonal heterogeneity in treatment resistance, the function of epigenetic modifiers, and the identification of synthetic lethal vulnerabilities. Gene-edited cell models enable precise dissection of these mechanisms in isogenic backgrounds, reducing confounding variables.

AML pathogenesis involves disruption of normal hematopoietic differentiation and uncontrolled proliferation. Key pathways include:

• • Class I mutations (proliferative): Activating mutations in FLT3, KIT, RAS, and JAK2 drive constitutive signaling through the MAPK and PI3K/AKT pathways.
• • Class II mutations (differentiation block): Mutations in transcription factors (RUNX1, CEBPA) and nucleophosmin (NPM1) impair myeloid differentiation.
• • Epigenetic modifiers: Mutations in DNMT3A, TET2, IDH1/2, and ASXL1 alter DNA methylation and histone modifications, leading to aberrant gene expression.
• • Tumor suppressor loss: TP53 mutations and deletions occur in about 8-10% of de novo AML and are associated with complex karyotypes and poor prognosis.

Several signaling networks are commonly deregulated in AML:

• • MAPK/ERK pathway: Constitutively activated by FLT3-ITD, RAS mutations, or KIT mutations. Key nodes: FLT3, KRAS/NRAS, BRAF, MEK, ERK.
• • PI3K/AKT/mTOR pathway: Activated downstream of FLT3 and RAS. Key nodes: PI3K, AKT, mTOR, S6K.
• • JAK/STAT pathway: Activated by FLT3-ITD and JAK2 mutations. Key nodes: JAK2, STAT3, STAT5.
• • Wnt/beta-catenin pathway: Often upregulated in AML stem cells. Key nodes: beta-catenin, LEF1, TCF.
• • NF-kB pathway: Constitutive activation contributes to survival. Key nodes: IKK, NF-kB, BCL-2.

Commonly used AML cell lines and their key mutations:

Organoid models are emerging as 3D culture systems that better recapitulate the bone marrow microenvironment and support long-term expansion of primary AML cells, enabling drug testing and clonal evolution studies.

• • Patient-derived xenograft (PDX) models: Engraftment of primary AML cells into immunodeficient mice (e.g., NSG). Preserves heterogeneity and allows in vivo drug testing.
• • Genetically engineered mouse models (GEMM): Conditional knock-in of FLT3-ITD, NPM1c, or MLL fusions. Used to study leukemogenesis and test targeted therapies.
• • Induced models: Retroviral or lentiviral transduction of human CD34+ cells with oncogenes (e.g., MLL-AF9) followed by transplantation into mice. Useful for rapid modeling.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications in a defined background. Examples include:

• • TP53 knockout: Generated in MOLM-13 or OCI-AML3 to study loss of tumor suppressor function and chemotherapy resistance.
• • FLT3-ITD knock-in: Introduction of ITD mutations into FLT3 wild-type lines (e.g., THP-1) to model constitutive FLT3 activation.
• • NPM1c knock-in: Introduction of the type A NPM1 mutation into wild-type lines to study cytoplasmic mislocalization.
• • IDH1 R132H knock-in: Introduction of the neomorphic mutation to study 2-HG production and epigenetic changes.

These sequence-verified, commercially available models accelerate research by providing clean genetic backgrounds, reducing the need for laborious cloning and validation. They are essential for target validation, drug screening, and mechanistic studies.

Gene-edited cell lines are used to validate the functional role of genes identified in genomic studies. For example:

• • TP53 knockout in OCI-AML3 cells confirmed the role of p53 in response to DNA-damaging agents like cytarabine.
• • NPM1c knock-in in THP-1 cells demonstrated that NPM1 mutation alone is sufficient to induce a differentiation block and alter HOX gene expression.
• • FLT3-ITD knock-in in wild-type lines showed that ITD mutations confer cytokine-independent growth and activate STAT5 signaling.

Isogenic pairs (e.g., wild-type vs. FLT3-ITD) are used to screen for selective inhibitors. For example:

• • Screening of FLT3 inhibitors (e.g., quizartinib, gilteritinib) in isogenic FLT3-ITD vs. wild-type lines identifies on-target effects and resistance mechanisms.
• • Resistance modeling: Chronic exposure of FLT3-ITD cells to inhibitors leads to acquired resistance mutations (e.g., FLT3 D835Y), which can be introduced via CRISPR to study resistance mechanisms.

CRISPR-based synthetic lethality screens in AML cell lines identify vulnerabilities that can be exploited therapeutically. For example:

• • A genome-wide CRISPR screen in NPM1c-mutant cells identified the dependency on the menin-MLL interaction, leading to the development of menin inhibitors.
• • Screens in IDH1/2-mutant cells revealed sensitivity to BCL-2 inhibitors (e.g., venetoclax), providing a biomarker for patient stratification.